Sustaining pneumococcal vaccination after transitioning from Gavi support: A modelling and cost-effectiveness study in Kenya
The Lancet Global Health Apr 19, 2019
Ojal J, et al. - In this modelling and cost-effectiveness study, researchers estimated the cost-effectiveness of continuing pneumococcal conjugate vaccine (PCV) using Gavi's schedule of vaccine prices, reaching a peak of $3.05 per dose in 2027, when Kenya becomes fully self-financing. To sustain its health gains, continued use of PCV is essential. Based on the $1,445 per capita Kenyan gross domestic product—and compared with other vaccines—continued use of PCV at full cost is cost-effective (based on the assumption that any reduction in disease will result in a reduction in mortality). While affordability is likely to be a concern, findings supported vaccine budget expansion in Kenya. The investigators predicted that $153 in 2032 would be the incremental cost per disability-adjusted life-year averted from continuing PCV.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
Sign up with M3 India to try daily quizzes and take part in competitionsTry M3 India / Log In
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor